Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. briscrew

BriScrew

BioResorbable Ostheosynthesis Implant

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 BriScrew project word cloud

Explore the words cloud of the BriScrew project. It provides you a very rough idea of what is the project "BriScrew" about.

qualified    merely    commercializing    minimize    fractures    sales    hospital    alloy    biodegradable    global    earn    performed    profit    operation    treatment    revolutionary    unpredictable    almost    implants    frequently    off    screw    engineering    extremely    surgery    team    infections    assurance    alloyed    steel    healthcare    ca    7m    gold    risks    injuries    mg    payback    quality    900    organism    healing    orthopaedic    purified    sell    stiff    titanium    2020    magnesium    medicine    materials    screws    stimulates    bioresorbable    too    stress    rare    bri    95    5    zn    patient    2m    zirconium    natural    q3    investment    introduce    conventional    pay    surgical    launch    generate    shielding    total    feeling    roi    13    osteosynthesis    consists    time    bone    commercialization    removal    employees    reduces    earth    remove    aluminium    adverse    prevent    standard    risk    81    foresee    market    pain    metal    hire    individuals    implant    disease    composition    secondary    silver    temperature   

Project "BriScrew" data sheet

The following table provides information about the project.

Coordinator		 BRI.TECH GMBH 

Organization address
address: ROSSMANNGASSE 21/4
city: GRAZ
postcode: 8010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Austria [AT]
 Project website http://britech.eu/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRI.TECH GMBH AT (GRAZ) coordinator 50˙000.00

Map

 Project objective

In the EU, 20 % of all hospital treated injuries are bone fractures. If surgical treatment of bone fractures is necessary, it is currently performed with standard metal implants. Conventional gold-standard titanium or steel implants are too stiff, have adverse effects on the patient (feeling of pain during temperature changes) and lead to stress-shielding. Their usage is associated to the risk of infections and bone loss. Often a secondary surgery for removal is needed which is associated with almost 50 % higher healthcare costs. When Mg-based implants are used they are frequently alloyed with rare earth elements, aluminium, silver or zirconium. However, zirconium reduces the healing properties, aluminium and rare earth elements may remain in the organism and can lead to unpredictable effects, while the application of silver might result in a silver-disease.

Within the BRI.SCREW project we will introduce to the market revolutionary osteosynthesis implants that do not need surgical removal. We will use our own bioresorbable magnesium alloy which consists merely out of extremely high purified natural materials including Mg, Ca and Zn. BRI.SCREW is 100 % biodegradable, stimulates the healing process of the bone and has no side effects due to the implant's composition. Our orthopaedic implants will prevent the need of a second operation to remove the implant and will therefore minimize patient costs and surgical risks.

Our team consists of highly qualified individuals with experience in medicine, engineering and quality assurance. The investment in BRI.SCREW will pay off. We have estimated that after 5 years from launch, we will sell in total 81.900 BRI.SCREWs (sales €13.2M), hire 10 technical employees, and manage 5% of the global market. We will earn €8.7M profit and generate a ROI of 3.95 by commercializing this technology. We foresee the payback time in 2 years after commercialization (in Q3 of 2020).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRISCREW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRISCREW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More